COMMUNIQUÉS West-GlobeNewswire

Caring Brands Secures Two New U.S. Patents Strengthening Hair Enzyme Booster Technology
03/02/2026
Fort Pierce, FL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced the issuance of two new United States patents covering proprietary methods and compositions designed to enhance [...]
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
03/02/2026
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of [...]
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
03/02/2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41 st Asia-Pacific Academy of Ophthalmology (APAO [...]
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
03/02/2026
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026
MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
03/02/2026
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable [...]
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
03/02/2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]
Mesa Labs Announces Third Quarter Results
03/02/2026
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
AdhereHealth Announces Appointment of CEO Kempton Presley and President & COO Patrick McNulty as Members of the Board of Directors
03/02/2026
NASHVILLE, Tenn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- AdhereHealth today announced the appointment of Kempton Presley, Chief Executive Officer, and Patrick “Pat” McNulty, President and Chief Operating Officer, as members [...]
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
03/02/2026
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 [...]
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026
This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
03/02/2026
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of miv-cel EMERYVILLE, [...]
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
03/02/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE [...]
Ardelyx Receives New Patent for Tenapanor
03/02/2026
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
03/02/2026
Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, [...]
Cynet Named a Strong Performer in 2026 Gartner Peer Insights™ “Voice of the Customer” for Endpoint Protection Platforms
03/02/2026
Customers cite Cynet’s “reliable endpoint protection” and “unified security platform” with 95% willingness to recommend BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cynet , the unified, AI-powered cybersecurity platform, [...]
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis [...]
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
03/02/2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today [...]

Pages